Hard luck or Fat Duck: Cards on the table for Avandia
This article was originally published in Scrip
Executive Summary
While no decisions were made on 5 June on the first of a two-day FDA advisory committee meeting convened to review data about GlaxoSmithKline's once-popular, but now restricted, Type II diabetes drug Avandia (rosiglitazone), regulators and the firm laid their cards on the table, with one US official even wagering that if he is proved wrong on his bet, he'll pony up for an expensive meal.